Ianalumab plus eltrombopag extends time to treatment failure in primary ITP adults.
Study tests ianalumab plus eltrombopag for adults with immune thrombocytopenia
This phase 3 randomized, double-blind trial in 152 adults with primary ITP and insufficient response to glucocorticoids found that ianalumab…
Adding ianalumab to standard therapy helped more adults with immune thrombocytopenia stay stable and avoid treatment failure compared to pla…
Rituximab exposure is associated with serum sickness in patients with multiple sclerosis, nephrotic syndrome, or immune thrombocytopenia.
Can taking Rituximab cause a severe allergic reaction that returns if you take it again?
This retrospective review analyzed 39 published case reports of patients with rituximab-induced serum sickness (RISS). The study describes c…
Taking Rituximab can trigger a delayed allergic reaction that returns in most patients if the drug is given again, so doctors must use extre…
Case report: CMML initially diagnosed as ITP in one patient, stabilized with decitabine
A single case shows leukemia can initially look like a different blood disorder
A case report describes one patient initially diagnosed with immune thrombocytopenia (ITP) who was later found to have chronic myelomonocyti…
A single case shows leukemia can initially look like a different blood disorder, so doctors must watch for hidden mutations when standard tr…